Banceu Cosmin Marian, Cristutiu Daiana, Gurzu Simona, Harpa Marius Mihai, Banceu Diana, Suciu Horatiu
Department ME 2, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania.
Emergency Institute for Cardiovascular Diseases and Transplantation Targu Mures, 540136 Targu Mures, Romania.
J Clin Med. 2025 Jul 12;14(14):4949. doi: 10.3390/jcm14144949.
Aortic stenosis (AS) is a progressive valvular heart disease marked by a restriction of blood flow through the aortic valve, resulting in considerable morbidity and mortality if not addressed. AS has historically been managed through surgical aortic valve replacement (SAVR), but there is a growing trend towards the use of transcatheter aortic valve replacement (TAVR). TAVR has transformed the management of symptomatic severe AS and is currently authorized for patients with varying levels of surgical risk. The rising application of TAVR in patients under 65 years presents a challenge for heart valve teams (HVTs) managing younger individuals whose life expectancy may surpass the durability of the valve. Patients over 65 years are typically treated with bioprosthetic tissue valves; however, there remains significant uncertainty regarding the selection between TAVR and SAVR.
主动脉瓣狭窄（AS）是一种进行性瓣膜性心脏病，其特征是通过主动脉瓣的血流受限，如果不加以治疗，会导致相当高的发病率和死亡率。过去，AS一直通过外科主动脉瓣置换术（SAVR）进行治疗，但目前经导管主动脉瓣置换术（TAVR）的使用趋势正在增加。TAVR改变了有症状的重度AS的治疗方式，目前已被批准用于具有不同手术风险水平的患者。TAVR在65岁以下患者中的应用不断增加，这给管理预期寿命可能超过瓣膜耐久性的年轻患者的心脏瓣膜团队（HVT）带来了挑战。65岁以上的患者通常使用生物人工组织瓣膜进行治疗；然而，在TAVR和SAVR之间的选择仍存在很大的不确定性。
